Agomab Therapeutics (AGMB) CDO details vested and vesting option grants

Rhea-AI Filing Summary

Agomab Therapeutics NV filed an initial ownership report for Chief Development Officer Andrea Saez Borderias, detailing multiple stock option awards over common shares. The options are held directly, with exercise prices of $0.0005 and $14.2600 per share and expirations ranging from 2031 to 2036. Footnotes state that some options are already fully vested and exercisable, while others vest over time in scheduled monthly installments, conditioned on continued service. The common shares may also be represented by American Depositary Shares on a one-for-one basis.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Borderias Andrea Saez

Role Chief Development Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 91,256 shares (Direct)

Footnotes (1)

1. The shares underlying this option are fully vested and exercisable. The common shares may be represented by American Depositary Shares, each of which currently represents one common share. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Borderias Andrea Saez

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	03/05/2031	Common shares(2)	91,256	$0.0005(3)	D
Stock Option (Right to Buy)	(1)	06/28/2032	Common shares(2)	28,139	$0.0005(3)	D
Stock Option (Right to Buy)	(1)	10/10/2033	Common shares(2)	163,940	$0.0005(3)	D
Stock Option (Right to Buy)	(4)	07/08/2034	Common shares(2)	5,671	$0.0005(3)	D
Stock Option (Right to Buy)	(4)	11/04/2034	Common shares(2)	122,641	$0.0005(3)	D
Stock Option (Right to Buy)	(5)	01/15/2036	Common shares(2)	174,507	$14.26(3)	D

Explanation of Responses:

1. The shares underlying this option are fully vested and exercisable.

2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

4. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

5. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 for Agomab Therapeutics (AGMB) disclose for Andrea Saez Borderias?

The Form 3 reports Chief Development Officer Andrea Saez Borderias’ stock option holdings in Agomab Therapeutics. It lists several direct stock option awards over common shares, including their exercise prices, expiration dates, vesting terms, and that some options are already fully vested and exercisable.

What stock options does the Agomab Therapeutics (AGMB) CDO hold according to this filing?

The filing lists multiple direct stock options over Agomab common shares with exercise prices of $0.0005 and $14.2600. Each grant specifies an expiration date between 2031 and 2036, along with the number of underlying common shares tied to that particular option award.

How do the Agomab Therapeutics (AGMB) CDO’s stock options vest?

Footnotes explain that one option grant is fully vested and exercisable, while others vest over time. One grant vests 50% on February 9, 2026 with the rest in 24 equal monthly installments, and another vests 25% on February 9, 2027 with the remainder in 36 monthly installments.

Are Agomab Therapeutics (AGMB) options exercisable into American Depositary Shares?

Yes. The filing notes that the common shares underlying the options may be represented by American Depositary Shares. Each American Depositary Share currently represents one common share, so exercising the options can result in either common shares or equivalent ADSs on a one-for-one basis.

In what currency are the Agomab Therapeutics (AGMB) option exercise prices reported?

Exercise prices are reported in U.S. dollars. A footnote clarifies they reflect conversion from euros to dollars at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026, providing transparent currency treatment for the option strike prices.

Does this Agomab Therapeutics (AGMB) Form 3 show any stock option exercises or sales?

The data classifies all entries as holdings, with no buy or sell transactions recorded. Transaction summaries show zero exercises, gifts, tax withholdings, or restructurings, indicating this Form 3 serves as a snapshot of existing derivative positions rather than reporting new trades.